Blue Sky Biotech, Inc Appoints Scott Gridley, Ph.D., as Senior Research Scientist
Worcester, MA, August 15, 2006 --(PR.com)-- Blue Sky Biotech, Inc. announced the June 1st appointment of Scott Gridley, Ph.D., as Senior Research Scientist. Dr. Gridley previously worked for five years in the metabolic diseases division of Sandoz Research Institute (now Novartis Institutes for BioMedical Research) where he was involved in the design, development and deployment of automated, cell-based, high-throughput screens for anti-diabetic compounds.
Scott received his doctorate from Dartmouth Medical School, Department of Microbiology and Immunology, for his work in biochemically purifying and characterizing a human protein complex (NELF) which represses RNA polymerase II transcriptional elongation and is specifically overcome by the HIV-1 Tat protein.
As a postdoctoral fellow, Scott joined the lab of Dr. Gustav Lienhard in the Biochemistry Department at Dartmouth. His research there focused on the insulin signaling pathway and led to the identification and characterization of several novel substrates of protein kinase B (Akt).
"Blue Sky is extending it’s brand across the Early Discovery Biology marketplace…The Company continues to steadily acquire knowledge and creativity across all business segments." "Dr. Gridley’s knowledge of disease-relevant biochemistry and cell biology aligns with our strategic trajectory" said Paul Wengender, Blue Sky Biotech President. “Dr. Gridley’s vision and experience in the area of metabolic diseases and drug discovery make him an excellent fit for Blue Sky Biotech’s business development strategy," added Dr. Norman Garceau, Chief Scientific Officer. Dr. Gridley will play a key role in product development.
The Company
Blue Sky Biotech, Inc. is an integrated service provider of “Gene To Screen” discovery biologicals. Currently, Blue Sky offers 3 linked laboratory service segments: Molecular Biology, Tissue Culture/Fermentation, and Protein Sciences (including biochemistry). This pre-clinical contract service bundle offers research-based drug discovery clients a convenient source of pharma-grade research tools. Services include Gene Synthesis, Vector Construction, Recombinant Protein Expression (bacterial, yeast, mammalian, insect), Stable Cell production, Protein Purification, and Assay Development. Blue Sky’s premium baculoviral (insect cell recombinant protein expression) service boasts a proprietary process technology (IKM®) that significantly improves turnaround time and enhances reproducibility. The Company is a privately held corporation, with 16 staff members. Blue Sky is located in Worcester, MA.
www.blueskybiotech.com
###
Scott received his doctorate from Dartmouth Medical School, Department of Microbiology and Immunology, for his work in biochemically purifying and characterizing a human protein complex (NELF) which represses RNA polymerase II transcriptional elongation and is specifically overcome by the HIV-1 Tat protein.
As a postdoctoral fellow, Scott joined the lab of Dr. Gustav Lienhard in the Biochemistry Department at Dartmouth. His research there focused on the insulin signaling pathway and led to the identification and characterization of several novel substrates of protein kinase B (Akt).
"Blue Sky is extending it’s brand across the Early Discovery Biology marketplace…The Company continues to steadily acquire knowledge and creativity across all business segments." "Dr. Gridley’s knowledge of disease-relevant biochemistry and cell biology aligns with our strategic trajectory" said Paul Wengender, Blue Sky Biotech President. “Dr. Gridley’s vision and experience in the area of metabolic diseases and drug discovery make him an excellent fit for Blue Sky Biotech’s business development strategy," added Dr. Norman Garceau, Chief Scientific Officer. Dr. Gridley will play a key role in product development.
The Company
Blue Sky Biotech, Inc. is an integrated service provider of “Gene To Screen” discovery biologicals. Currently, Blue Sky offers 3 linked laboratory service segments: Molecular Biology, Tissue Culture/Fermentation, and Protein Sciences (including biochemistry). This pre-clinical contract service bundle offers research-based drug discovery clients a convenient source of pharma-grade research tools. Services include Gene Synthesis, Vector Construction, Recombinant Protein Expression (bacterial, yeast, mammalian, insect), Stable Cell production, Protein Purification, and Assay Development. Blue Sky’s premium baculoviral (insect cell recombinant protein expression) service boasts a proprietary process technology (IKM®) that significantly improves turnaround time and enhances reproducibility. The Company is a privately held corporation, with 16 staff members. Blue Sky is located in Worcester, MA.
www.blueskybiotech.com
###
Contact
Blue Sky Biotech, Inc.
Paul Wengender
1-800-383-7795
BlueSkyBiotech.com
Paul Wengender
1-800-383-7795
BlueSkyBiotech.com
Contact
Categories